$RDNT

RadNet (RDNT) To Report Earnings Tomorrow: Here Is What To Expect

RadNet (NASDAQ:RDNT) will report earnings next after market close. The article notes last quarter’s revenue of $575.6M, up 22.1% YoY, but a miss on EPS. For the upcoming quarter, analysts expect revenue growth of 22.1% YoY. It cites an average analyst price target of $89.75 versus $71.57 and mentions peer results from Quest and Guardant Health.

Original reporting
Published Aug 11, 2026, 5:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 5:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
RadNet (RDNT) To Report Earnings Tomorrow: Here Is What To Expect — source image
Decision brief

The 30-second read

$RDNTNeutralMed
01

Why it matters

The main tradable element is the earnings event timing and the market’s expectations for revenue growth; however, the text does not include any new company disclosure such as updated guidance, a new contract, or a regulatory development.

02

Market read

Traders can position for earnings volatility using the provided consensus revenue growth framing and the reminder that EPS previously missed, but there is no new guidance in the article.

03

What to watch

No details are provided on guidance, cash flow, or segment trends; traders should focus on EPS drivers and any commentary on utilization, reimbursement, and pricing that are not covered here.

Relevance 5/10Novelty 4/10Timing: pre-earnings, tomorrow after market close

Background

The article previews RadNet’s upcoming earnings release and summarizes last quarter’s revenue beat alongside an EPS miss, then compares peer results in the same segment.

Company-level read

Ticker impact

$RDNTNeutralMedium confidence
Context

RadNet (RDNT) is scheduled to report earnings tomorrow after the close, with the article citing consensus revenue growth and prior quarter results.

Expected impact

Likely elevated volatility into the print, with direction dependent on EPS versus the already-cited prior miss and any updated commentary.

Evidence & confidence

The newest concrete item is the scheduled earnings timing, plus consensus framing (revenue growth) and last quarter’s revenue beat and EPS miss; there is no fresh company disclosure in the text.

Market effects

Testing and diagnostics services names are referenced as having reported results, which can influence sector sentiment around earnings season.

Primarily US-focused, with NASDAQ-listed peers cited for read-through.

Limited, as the piece is centered on a single US company’s earnings timing and US-listed peer reactions.

Counterpoint

The article emphasizes revenue growth and price targets, but the prior quarter included a significant EPS miss, which can dominate the stock reaction if margins or costs disappoint again.

Key entities

  • RadNet

    NASDAQ-listed diagnostic imaging company scheduled to report earnings tomorrow after market close.

  • Quest Diagnostics

    Peer cited as having reported Q2 results with year-on-year revenue growth and a post-results stock move.

  • Guardant Health

    Peer cited as having reported Q2 revenues up year on year and a post-results stock move.

Related articles

$RDNTHighAI 8/10

Truist reiterates Buy on RadNet stock after ONRAD acquisition

Truist Securities reiterated a Buy rating and $94 price target on RadNet (RDNT) after its $700M acquisition of ONRAD. The deal includes cash, shares, and an earnout. RadNet's stock trades at $73.77, with analysts citing growth potential. The company reported strong Q2 2026 results, raising guidance and prompting price target increases from multiple analysts.

HighAI 9/10

RadNet acquires ONRAD in $355m deal to broaden radiology provision

RadNet agreed to acquire ONRAD for $355m ($350m cash, $5m shares) with a potential $210m earnout. The deal, expected to close in early 2027, aims to expand RadNet's radiology services and address staffing shortages. RadNet plans to integrate ONRAD's teleradiology and staffing services with its AI-based solutions to improve efficiency and patient care. Jefferies analysts called it a 'sound transaction.'

$RDNTHighAI 8/10

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

Guardant Health, RadNet (NASDAQ:RDNT), Labcorp (NYSE:LH), NeoGenomics (NASDAQ:NEO), and Quest (NYSE:DGX) reported Q2 results. RadNet saw 25% revenue growth, beating estimates. Labcorp's revenue grew 5.8%, meeting expectations but underperforming peers. NeoGenomics and Quest both beat estimates with 11.2% and 10.2% revenue growth, respectively. Stocks have risen since reporting.

$RDNTMed

RadNet (RDNT) Posts Record Revenue But Profit Growth Lags

RadNet (RDNT) reported Q2 2026 revenue of $622.7M, up 25% YoY, and raised full-year guidance. Profit growth lagged, with net income falling to $7.5M from $14.5M YoY. Digital Health revenue grew 56.5%, but its EBITDA dropped 27.2%. Hedge fund ownership declined, while short interest remains high at 14.56%.